Biotech | August 10, 2021
Eagle Pharmaceuticals announces licensing agreement for Landiolol
Deal signed with AOP Orphan for US commercial rights
Deal signed with AOP Orphan for US commercial rights
Forex gains stood at Rs 20 crore for the quarter
Board approves fundraise of Rs 1500 crore
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
This robust growth has come despite the raging pandemic for most part of the quarter
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Total income grew in the quarter
Subscribe To Our Newsletter & Stay Updated
